D&A at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Corcept Therapeutics's D&A?
- Corcept Therapeutics (CORT) reported D&A of $598K in Q1 2026.
- How has Corcept Therapeutics's D&A changed year-over-year?
- Corcept Therapeutics's D&A increased by 109.8% year-over-year, from $285K to $598K.
- What is the long-term trend for Corcept Therapeutics's D&A?
- Over 4 years (2021 to 2025), Corcept Therapeutics's D&A has grown at a -2.4% compound annual growth rate (CAGR), from $1.07M to $972K.